ArticleScientific reports2026
Drug-drug interactions with direct oral anticoagulants in Belgian primary care patients with non-valvular atrial fibrillation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Direct oral anticoagulants (DOACs) are widely prescribed in primary care, but co-prescription with interacting drugs may increase thromboembolic and major bleeding risks. We conducted a retrospective cohort study in Belgium in 2022-2023 using the real-world THIN database to evaluate the prevalence of DOAC-related drug-drug interactions (DDIs) in general practitioners' (GPs) prescriptions for patients with non-valvular atrial fibrillation (NVAF) and to assess factors associated with pharmacodynamic DDIs. DDIs were defined as the co-prescription of a DOAC and an interacting drug within the same week. Factors associated with pharmacodynamic DDIs were assessed using multivariable logistic regression. Among 5,637 patients receiving 13,334 DOAC prescriptions, 22.9% had at least one DDI during the year. Overall, 17.8% of GP-issued DOAC prescriptions involved a DDI, of which 91.5% were pharmacodynamic. The most frequently interacting drug classes were selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors (44.2%), antiplatelets (22.6%) and non-steroidal anti-inflammatory drugs (19.6%). Higher CHA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.